Table 1. Efficacy of the single and combined treatments in various cancer types.
| Cell line | Tissue | DNA Repair defects | Survival (%/NT)
|
|||
|---|---|---|---|---|---|---|
| Ola | AsiDNA | AsiDNA + Ola | Calculated additivity | |||
| HeLa CTL KD | Cervix | - | 97.2 | 69.0 | 35.4 | 67.1 |
| HeLa PARP1 KD | PARP1 | 100.5 | 49.3 | 47.6 | 49.5 | |
| HeLa CTL SX | - | 105.1 | 96.4 | 79.5 | 101.3 | |
| HeLa BRCA1 SX | BRCA1 | 71.4 | 64.6 | 27.9 | 46.2 | |
| HeLa BRCA2 SX | BRCA2 | 65.0 | 69.3 | 15.1 | 45.1 | |
|
| ||||||
| Hep2 | Head and neck | - | 101 | 69.4 | 42.5 | 70 |
|
| ||||||
| MO59K | Brain | - | 117.3 | 75.4 | 28.7 | 88.5 |
| MO59J | DNA-PKcs | 87.5 | 51.2 | 21.3 | 44.9 | |
|
| ||||||
| SK28 Lsh CTL | Skin | - | 80.6 | 70.3 | 34.8 | 56.7 |
| SK28 Lsh DNA-PKcs | DNA-PKcs | 80.9 | 50.8 | 33.6 | 41.1 | |
|
| ||||||
| HCT116 | Colon | - | 82.9 | 80.0 | 36.6 | 66.3 |
| HCT116 KU70+/- | KU70 | 88.6 | 77.3 | 42.3 | 68.5 | |
|
| ||||||
| Hut78 | Blood | - | 85.8 | 51.1 | 39.1 | 43.8 |
| IM9 | - | 84.6 | 20.3 | 4.6 | 17.1 | |
| Jurkat | - | 68.4 | 45.2 | 28.5 | 31.0 | |
|
| ||||||
| MDAMB231 | Breast | - | 90.9 | 87.2 | 33.5 | 79.2 |
| BC173 | - | 94.4 | 54.5 | 39.3 | 51.4 | |
| BC227 | BRCA2 | 75.3 | 69.8 | 42.6 | 52.6 | |
| HCC38 | BRCA1 | 66.7 | 69.5 | 25.7 | 46.3 | |
| HCC1187 | - | 61.5 | 103.8 | 41.5 | 63.9 | |
| MDAMB468 | - | 68.3 | 53.7 | 28.0 | 36.6 | |
|
| ||||||
| MCF10A | Breast - non tumor | - | 86.2 | 91.7 | 87.5 | 79.0 |
| MCF12A | - | 88.5 | 97.2 | 90.1 | 86.1 | |
Concentrations used were 4.8μM of AsiDNA and 0.1μM of Ola. Calculated additivity = survival to AsiDNA x survival to Ola.